| Entry |
|
|---|
| Name |
Trastuzumab duocarmazine (USAN/INN) |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Alkylating agent, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody |
|---|
| Type |
Antibody-drug conjugate |
|---|
| Target |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD05 Trastuzumab duocarmazine
D11375 Trastuzumab duocarmazine (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
D11375 Trastuzumab duocarmazine
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
ERBB2 (HER2, CD340)
D11375 Trastuzumab duocarmazine (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
